Unsplash
Unsplash
The Food and Drug Administration (FDA) said last Friday that AstraZeneca’s preventative monoclonal antibody treatment for COVID-19 is likely ineffective against the XBB.1.5 omicron subvariant due to its similarity to other mutations of the virus that are also not neutralized by the treatment. In a statement, the FDA said it “does not anticipate that Evusheld will neutralize XBB.1.5.” Evusheld is a combination of two monoclonal antibodies that has been authorized as a pre-exposure prophylaxis to prevent COVID-19 infections in those who are moderately to severely immunocompromised. Learn more from The Hill here. See the next article to learn more about XBB.1.5.
Original source can be found here.
Alerts Sign-up